{"id":60230,"date":"2024-10-24T22:08:08","date_gmt":"2024-10-24T20:08:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\/"},"modified":"2024-10-24T22:08:08","modified_gmt":"2024-10-24T20:08:08","slug":"hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\/","title":{"rendered":"Hyperfine, Inc. to Announce Third Quarter 2024 Financial Results on November 12, 2024"},"content":{"rendered":"
\n

GUILFORD, Conn.–(BUSINESS WIRE)–Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system\u2014the Swoop\u00ae system\u2014today announced that it will report financial results for the third quarter 2024 on Tuesday, November 12, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time \/ 4:30 p.m. Eastern Time.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nA live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.\u2019s corporate website at https:\/\/investors.hyperfine.io\/<\/a>. Participants are encouraged to register more than 15 minutes before the start of the call.\n<\/p>\n

\nAbout the Swoop\u00ae Portable MR Imaging\u00ae System<\/b>\n<\/p>\n

\nThe Swoop\u00ae Portable MR Imaging\u00ae system is U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. It is a portable, ultra-low-field magnetic resonance imaging device for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop\u00ae system also has CE certification in the European Union and UKCA certification in the United Kingdom. The Swoop\u00ae system is commercially available in a select number of international markets.\n<\/p>\n

\nAbout Hyperfine, Inc.<\/b>\n<\/p>\n

\nHyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop\u00ae system\u2014the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop\u00ae system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit hyperfine.io.\n<\/p>\n

\nThe Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc..\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact
\n
<\/b>Webb Campbell
\n
Gilmartin Group LLC
\n
webb@gilmartinir.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

GUILFORD, Conn.–(BUSINESS WIRE)–Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system\u2014the Swoop\u00ae system\u2014today announced that it will report financial results for the third quarter 2024 on Tuesday, November 12, 2024. Management will host a corresponding conference call at 1:30 … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-60230","6":"format-standard","7":"category-industry"},"yoast_head":"\nHyperfine, Inc. to Announce Third Quarter 2024 Financial Results on November 12, 2024 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hyperfine, Inc. to Announce Third Quarter 2024 Financial Results on November 12, 2024 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"GUILFORD, Conn.–(BUSINESS WIRE)–Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system\u2014the Swoop\u00ae system\u2014today announced that it will report financial results for the third quarter 2024 on Tuesday, November 12, 2024. Management will host a corresponding conference call at 1:30 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-24T20:08:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20241024379840\/en\/1947478\/22\/Hyperfine_Logomark_Full_Color_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Hyperfine, Inc. to Announce Third Quarter 2024 Financial Results on November 12, 2024\",\"datePublished\":\"2024-10-24T20:08:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\\\/\"},\"wordCount\":355,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241024379840\\\/en\\\/1947478\\\/22\\\/Hyperfine_Logomark_Full_Color_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\\\/\",\"name\":\"Hyperfine, Inc. to Announce Third Quarter 2024 Financial Results on November 12, 2024 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241024379840\\\/en\\\/1947478\\\/22\\\/Hyperfine_Logomark_Full_Color_RGB.jpg\",\"datePublished\":\"2024-10-24T20:08:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241024379840\\\/en\\\/1947478\\\/22\\\/Hyperfine_Logomark_Full_Color_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20241024379840\\\/en\\\/1947478\\\/22\\\/Hyperfine_Logomark_Full_Color_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hyperfine, Inc. to Announce Third Quarter 2024 Financial Results on November 12, 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hyperfine, Inc. to Announce Third Quarter 2024 Financial Results on November 12, 2024 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\/","og_locale":"en_US","og_type":"article","og_title":"Hyperfine, Inc. to Announce Third Quarter 2024 Financial Results on November 12, 2024 - Pharma Trend","og_description":"GUILFORD, Conn.–(BUSINESS WIRE)–Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system\u2014the Swoop\u00ae system\u2014today announced that it will report financial results for the third quarter 2024 on Tuesday, November 12, 2024. Management will host a corresponding conference call at 1:30 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\/","og_site_name":"Pharma Trend","article_published_time":"2024-10-24T20:08:08+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20241024379840\/en\/1947478\/22\/Hyperfine_Logomark_Full_Color_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Hyperfine, Inc. to Announce Third Quarter 2024 Financial Results on November 12, 2024","datePublished":"2024-10-24T20:08:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\/"},"wordCount":355,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241024379840\/en\/1947478\/22\/Hyperfine_Logomark_Full_Color_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\/","url":"https:\/\/pharma-trend.com\/en\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\/","name":"Hyperfine, Inc. to Announce Third Quarter 2024 Financial Results on November 12, 2024 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20241024379840\/en\/1947478\/22\/Hyperfine_Logomark_Full_Color_RGB.jpg","datePublished":"2024-10-24T20:08:08+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20241024379840\/en\/1947478\/22\/Hyperfine_Logomark_Full_Color_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20241024379840\/en\/1947478\/22\/Hyperfine_Logomark_Full_Color_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/hyperfine-inc-to-announce-third-quarter-2024-financial-results-on-november-12-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Hyperfine, Inc. to Announce Third Quarter 2024 Financial Results on November 12, 2024"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=60230"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/60230\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=60230"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=60230"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=60230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}